To test whether primitive hematopoietic stem cells (PHSCs) are stlmulated by Steel (SI) factor (c-kit ligand) in vivo, donor mice were studied after three or seven daily injections of SI factor. PHSC activity was measured as long-term erythroid and lymphoid competitive repopulating ability. Cells t o be tested (usually marrow or spleen cells from treated donors) were mixed with untreated competitor marrow that produces erythrocytes and lymphocytes that are genetically distinguishable from the donors by differences in hemoglobin (Hb) and glucosephosphate isomerase (GPI) markers. These cell mixtures were injected into lethally irradiated hosts, and after 111 t o 293 days, functional abilities of donor PHSC populations were assessed and expressed as percentages of donor-type Hb and GP1 in the host's circulating erythrocytes and lymphocytes, respectively. A striking increase in
splenic PHSC activity occurred after seven daily injections of SI factor, with a much smaller increase after three daily injections. Both three and seven daily injections of SI factor slightly reduced marrow PHSC activity. Rapid cycling greatly increases PHSC vulnerability t o 5-fluorouracil (5FU). To test whether SI factor stimulates PHSCs into rapid cycling, donor mice were given a dose of 5FU in addition t o SI factor. The increase in splenic PHSCs after 7 days of treatment with SI factor occurred t o a similar degree whether donors were or were not treated with 5FU on day 8. However, a dose of 5FU on day 4 of the SI factor treatments almost totally prevented the increase in splenic PHSC activity. Apparently this increased activity requires PHSC cycling throughout the period of SI factor treatment. pressed on S% to 10% of mouse marrow and on 70% to 80% of a highly enriched multipotent stem cell fraction, although this fraction increases in SZIS1 mutant fetuses that lack functional S1 factor.14 The variety of activities of S1 factor and the wide range of distribution of c-kit suggest that S1 factor is important in early stages of myeloid and lymphoid cell development, and may affect PHSC proliferation. PHSCs are defined by maximal ability to repopulate both the hematopoietic and immune systems, and to differentiate into both myeloid and lymphoid lineages, over many month^.'^"^ Our competitive repopulation assay characterizes PHSC functions by assessing their ability to produce erythrocytes (Es) and lymphocytes (Ls) over time periods long enough to include a large portion of the life span.
This requires functional competency of all intermediary precursors descended from the PHSC. Therefore, for the PHSC to be measured as having normal repopulating ability, it and all of its descendants must function normally. Although the regenerating hematopoietic system has undergone numerous amplifying divisions in the transplant recipient, the competency of a PHSC is ultimately shown by its differentiated descendants.
In the present study, S1 factor increases splenic PHSC functional activities greatly, and cell proliferation is required while S1 factor is being given. The competitive repopulation with daily doses of S1 factor for 3 or 7 days. The large increase in splenic PHSC function after 7 days is abrogated by a single dose of S-fluorouracil (5FU) on day 4. This implicates cell proliferation because proliferating cells are sensitive to 5FU.l' assay17Jx IS ' used to evaluate PHSC function in donors treated
MATERIALS AND METHODS
Mice. The mice used in these experiments were C57BU6J (B6) and B6-HbbdGpi-l" congenic male mice, prepared as detailed prev i o~s l y . '~ All mice were 3 to 5 months old and were produced and maintained at The Jackson Laboratory, which is fully accredited by the American Association for the Accreditation of Laboratory Animal Care. Mice were fed the 96WA diet (Old Guilford, Guilford, CT) and were housed four per cage in a room free of known mouse pathogens. Details of the animal husbandry are published by the Jackson Laboratory (Bar Harbor, ME) in its brochure the Handbook on Genetically Standardized J a r Mice; quarterly updates are published in the Jackson Laborarory brochure Animal Health and Genetic Quality Control Report. Donor treatment and competitive repopulation. SI factor was kindly donated by Amgen, Inc (Thousand Oaks, CA 91320) as rat SCF-PEG (lot RS5) at a concentration of l . 16 mg/mL. Stock material was diluted with Hanks' Balanced Salt Solution (HBSS) to 30 pg/ mL and 100 pgkg was injected subcutaneously once a day (0.1 mL for a 30-g mouse). Controls were injected subcutaneously with 0.1 mL HBSS each day. Injection sites were varied daily to prevent local tissue necrosis. Stock solutions of 5FU (Sigma Chemical CO, St Louis, MO) were prepared in physiologic saline at a concentration of 10 mg/mL. Each treated mouse received 1.5 mg of 5FU per 10g body weight via a tail vein.
In experiment 1, donor cells were taken 1 day after the last of zero, three, or seven daily injection of S1 factor; mice receiving zero or three injections were handled and injected a total of seven times using daily control injections with HBSS. The same schedule of S1 factor and control injections was used in experiment 2, but half the donors getting zero, three, or seven daily injections of S1 factor then received 5FU 4 hours after the last injection, and in all cases, donor cells were taken 4 days after the last injection. In experiment 3, mice received seven daily injections with HBSS or with S1 factor. Half of those getting SI factor also received 5FU on the fourth day, 4 hours after the SI factor injection; donor cells were taken 1 day after the seventh daily control or S1 factor injection.
Bone marrow (BM) cells were suspended by flushing both femurs and tibias through a 1 .O-mL disposable syringe pressed gently against the bottom of a 4-mL test tube to break up clumps, whereas spleens were gently homogenized using ground glass homogenizers; both were suspended in Iscove's Modified Dulbecco's medium (Sigma) and the suspensions were filtered through nylon mesh to remove cell debris. In experiment 3, liver was suspended as described above for spleen. In experiment 3 only, donor cells were separated by density from splenic, blood, and liver suspensions; the fraction mixed with competitor marrow and injected into recipients had the same density as lymphocytes after separation on Lymphocyte Separating Medium (LSM, a Ficoll solution; Organon Teknika Corp, Durham, NC; no. 8410-01). Nucleated cells were counted using a model ZBI Coulter Counter (Coulter Electronics Inc. Hialeah, FL), after Es were lysed using standard lysing agents for white blood cell counting.
In experiment 1, donor and competitor cells were mixed in appropriate amounts after counting, whereas in experiments 2 and 3, counted numbers of competitor cells were mixed with fractions of donor cells prepared as follows: each donor and competitor cell suspension was made up to 3 mL per mouse, and although numbers of cells were different, equal volumes were used to provide equal proportions of donor tissues. Competitor (B6 type) marrow came from a single pool in each experiment, and for each donor treatment, donor cells were mixed with corresponding portions from the competitor pool. Each recipient was warmed and given 0.5 mL of the cell mixture injected intravenously via the lateral tail vein.
All recipients were B6 male mice lethally irradiated with 1,050 or 1,100 rads from a I3'Cs gamma source (Shepard Mark 1 ; Shepard & Associates, Glendale, CA) at a dose rate of 180 raddmin, 2 to 6 hours before transplantation. Donors were B6-HbbdGpi-I" males and the percentage of donor-type hemoglobin (Hbbd) and GP1 (GPI-I") in circulating Es and Ls, respectively, was assessed between 4 and 14 months after transplantation. The percentage of donor-type cells reflects the long-term repopulating ability of the PHSC present in the original donor sample relative to a constant competitor dose in each experiment.
Percentages of donor-type cells. Blood was taken from the orbital sinus in standard heparinized hematocrit tubes; Es and Ls were separated by density gradient centrifugation. Details of the separa-tion, and of the Hb and GP1 electrophoretic techniques, have been described previously." At the Hbb locus, B6 mice have the Hbb' (S, single) Hb allele that forms an electrophoretic band migrating farthest from negative to positive on the standard cellulose acetate gels used, whereas Hbbd (d, diffuse) Hb has the Hbb-bZd and Hbb-b2d bands that are intermediate and slowest migrating, respectively. B6 mice have the GPI-lb allele at the glucosephosphate isomerase (GPI-I) locus; on electrophoresis this type forms a more rapidly migrating band from positive to negative than does the GPI-I" allele. All gels were scanned using a Cliniscan 2 Scanning Densitometer (Helena Laboratories, Beaumont, TX). GP1 gels were scanned while still moist and without removing the staining gel.
The significance of differences between groups in percentages of donor-type cells was determined by 3-factor (experiment 1, 2) or 2factor (experiment 3) analyses of variance (ANOVAs), using the StatView I1 (version 1.04, Abacus Concepts, Berkeley, CA) program on a Macintosh SW30 personal computer (Apple Computer, Cupertino, CA). The factors were time (recipients sampled after 5 or 10 months in experiments 1 and 2). cell type (percent E or L) and treatment (0, 3, or 7 days of SI factor, with or without 5FU). P values are reported in the Table footnotes if they are equal to or less than 0.05, indicating significant factor effects. Analysis of factor interactions had no P less than .19, and most were greater than S , indicating no significant effects. The relative repopulating ability of each sample is also shown as repopulating units (RU) where 1 RU is the repopulating ability of 1 X IOs standard competitor marrow cells. The number of RU in the injected dose of donor cells is calculated as the ratio of the donor RU to the total RU as follows: measured % donor type = IOO(RU(donor)/RU(donor) + RU(competitor)). For example, in experiment l , 40 X IO5 competitor cells were used, so that RU(competitor) = 40. Thus, if RU(donor) is called RUD, and % donor type is called P,: PD = 100RUd(RUD + 40) and by algebra, RU, = PD40/( 100 -PD).
RESULTS
In experiment 1 (Table l) , seven daily doses of S1 factor greatly increased the repopulating ability of splenic cells, and three or seven daily doses of S1 factor slightly reduced the long-term repopulating ability of marrow. Although the day 0 splenic data had high standard deviations, independent measures in percent E and L at 165 days and 293 days all gave reproducible results ranging from 62% to 69%. The total RU in the day 0 spleen sample was 315 and 368, about half of the total RU in the B M sample (656 and 781). In mice given S1 factor daily for 7 days, the splenic RU increased about 10 fold from 315 and 368 RU to 2,940 and 4,410 RU. Nucleated cells in the circulating blood also increased from 11 million per milliliter at day 0 to 15 and 27 million per milliliter at days 3 and 7, respectively (data not shown). Whereas marrow cellularity did not change after 7 days of S1 factor, cellularity of the spleen increased from 105 X lo6 to 210 X lo6. The concentration of RU in the spleen did not change after 3 days of SL factor treatment, but after 7 days, it increased from 3 to 4, to 12 to 31, and was higher than BM RU concentrations at day 0 (10 to 16). Experiment 2 ( Table 2 ) repeated experiment l in donors labeled "No 5FU" with the exception that the donors were used 4 days after the last S1 factor injection. In addition, Table 2 reports effects of treatment with 5FU after the last with 4 x IO6 marrow cells or 20 x lo6 spleen cells from B6-Hbbd GP{-7" donors; donor cells were sampled 7 day after seven daily injections: 0 days of SI factor (7 days of HBSS), 4 days of HBSS and 3 days of SI factor, or 7 days of SI factor. Percentages of donor-type erythrocytes (%E) and lymphocytes (%L) were measured in recipient blood 165 and 293 days after transplantation, and are given as mean i-SD; there were four recipients for each value, except three with 3-day spleen. By ANOVA, in marrows %E was greater than %L ( P = ,004) and both %E or %L were reduced by treatment with SI factor ( P = .0001); in spleens, %E or %L were increased after 7 days of SI factor ( P = ,015). Collecting the data after 165 or 293 days had no significant effect. * RU are given per lo6 cells injected. By definition, one RU has the repopulating ability of 1 x lo5 fresh competitor marrow cells.
t Original number of cells obtained x IO6 in the two femurs and tibias removed from each donor, or in the entire spleen; Flulot is the total RU for that cell number.
dose of S1 factor. Most importantly, again there was a striking increase in splenic long-term repopulating ability after 7 daily S1 factor treatments. Total RUs after 160 and 288 days, respectively, increased from 75 and 113 in untreated donors, to 5 IO and 565 in donors given 7 S1 factor injections. This increase is less dramatic than experiment I , probably because cells were taken from the donors 4 days, rather than 1 day, after the last S1 factor injection. S1 factor treatment again seemed to reduce marrow function, but in Table 2 , these reductions were not statistically significant. Although such damage was not seen in previous ~tudies,'~.'' donors treated with 5FU had reduced repopulating ability regardless of treatment with S1 factor, suggesting generalized PHSC damage from this drug. Total splenic RU after 160 and 288 days, respectively, in untreated donors given 5FU were 53 and 55, whereas 7 days of S1 factor increased total splenic RU strikingly, to 168 and 193. The effects of 7 S1 factor injections on repopulating abilities of donor spleen were statistically significant whether 5FU was used or not. Figure l graphically shows that effects of S1 factor on splenic repopulating ability are reduced by 5Eu in experiment 2. Over the 7-day S1 factor treatment period, longterm repopulating ability of BM declined slightly. Splenic repopulating ability increased slightly after 3 days of S1 factor treatment, and increased greatly after 7 days. Relative increases in total splenic repopulating ability were 500% after 7 daily treatments with S1 factor without 5FU, and 351% in mice given 5FU. Thus, 5FU given on day 8 did not deplete all of the increase in repopulating ability associated with 7 days of S1 factor treatment. Possibly many PHSC that respond to S1 factor cease rapidly cycling by day 8 so that they are no longer vulnerable to SFU. This possibility is tested by giving 5FU in the middle of the S1 factor treatment schedule in experiment 3. Experiment 3 ( Table 3) again showed a striking increase in splenic long-term repopulating ability after 7 daily S1 factor treatments, with total splenic RU increasing from 2.1 to 303. Values were probably low, especially in untreated donors, because some PHSC activity was lost when spleen cells were fractionated on LSM and only cells having the same density as lymphocytes were used. Nevertheless, the effect of 5Fu given at day 4 during the 7 days of treatment with S1 factor was clear and striking; total splenic RU were 8.7, showing that the effects of S1 factor were abrogated.
Effects of S1 factor treatment on marrow were insignificant, whether 5Eu was or was not used. S1 factor appeared to slightly increase long-term lymphoid (but not erythroid) repopulating ability of circulating blood cells, and this was totally abrogated by 5FU. Liver cells had little or no repopulating ability in any group. There was no evidence that large numbers of PHSC were moving through the circulating blood or developing in the liver in significantly detectable amounts. Table 3 are for differentiated cell production in recipients 111 days after blood, liver, marrow, or spleen cell transplantation in mixtures with genetically distinguishable competitors. The same recipients were also tested after 9 and 14 months; complete data are not shown because values for most groups remained essentially the same. There were only two significant changes: repopulating abilities were higher in control ("no factor") spleens with total RU increasing from 2. l after 11 1 days to 31 (percent E = 22, percent L = IO) after 14 months. Also repopulating abilities were higher in blood cells from donors given SI Table 1 ;
Data shown in
the 5FU group was treated the same, but was then given 5FU the day of the last SI factor or control injection; in all cases, donor cells were collected 4 days after the last injection and were mixed with competitor marrow from the same pool. There were an average of 3.5 recipients per value. By ANOVA, %E was greater than %L ( P = .05) in No 5FU marrows; there were no significant effects in 5FU marrows. In both No 5FU and 5FU groups, splenic %E or %L increased significantly after 7 days of SI factor ( P = .002 and P = .04). Despite high variabilities in untreated controls (day O), independent measures of %E and %L at both 160 and 288 days gave reproducible results. Collecting the data after 160 or 288 days had no significant effect. * RU in 1/30 marrow cells or 1/5 spleen cells, so RU, , is found by simply multiplying mean RUE and RUL by 30 and 5 for marrow and spleen, respectively. Total number of donor cells x 10' for No 5FU (left to right as in Table) factor for 7 days ("S1 factor"), with total RU increasing from 2.1 after l 1 1 days to 6.5 (percent E = 20, percent L = 27) after 14 months.
DISCUSSION
PHSC are the most primitive precursors responsible for producing differentiated cells in both lymphoid and myeloid pathways over large fractions of the mouse life span. We determine PHSC function by measuring long-term competitive repopulating ability in vivo. Measured doses of donor hematopoietic cells of unknown repopulating potential are mixed with competitor stem cells differing at hemoglobin (Hbbd) and GP1 (GPI-I") genetic loci, and injected into lethally irradiated recipients. After allowing for proliferation and differentiation of the input cells, the recipients are assayed for the percentages of donor and competitor genotypes present in their Es and Ls. The contribution of each unknown donor type is compared with a standard adult marrow competitor. Thus, repopulating abilities of all unknown donors are easily compared because they are all defined relative to the standard competitor.17
Although it requires long periods of time, competitive repopulation is useful because it directly measures precursor performance. Short-term measures, such as the many assays of repopulating abilities of transplanted marrow?1,22 blood,23 or marrow cultures,24 and life-sparing abilities of spleen cells,2' as well as assays of C m -S and low-and high-proliferative potential in vitro colony forming cells, fail to predict long-term restoration of hematopoiesis by transplanted marrow.26,2' With no colony forming or other short-term assay for PHSC, the only definitive measure is to assess their longterm function in vivo. 26 Although marrow is normally the major site of PHSC activity in adult mice, the effect of S1 factor in vivo is to greatly increase PHSC activity in the spleen, with a slight deleterious effect on marrow activity. This increase in PHSC may begin after three daily infusions of S1 factor, but a major effect appears after 7 days of treatment (Tables 1 to 3) and may be the result of exponential growth (Fig 1) . PHSC migration may account for the loss in marrow activity in Tables 1 and 2; S1 factor in vivo may also have slight toxic effects on marrow PHSC. No. Days Donors Given S1 Factor The increase in splenic PHSC from S1 factor is very vulnerable to 5FU when it is administered in the middle of the S1 factor treatment period (Table 3) . Apparently, continuous PHSC stimulation by S1 factor is essential, not only for the increase in splenic PHSC function, but also for the rapid cycling that makes PHSC vulnerable to 5FU. Experiment 3 shows that the increase in splenic PHSC activity resulting from S1 factor requires rapid cell cycling on day 4 during the 7-day S1 factor treatment schedule. Therefore, we suggest that continuous S1 factor treatment stimulates PHSC proliferation.
In contrast, on day 8, after 7 days of S1 factor treatment, many splenic PHSC are not cycling rapidly enough to have increased vulnerability to 5FU ( Table 2 and Fig 1) . If the new splenic PHSC were rapidly dividing, we would expect to see a loss of splenic RU in the 5FU-treated samples to the level of the untreated Instead there is a 35 1 % increase in total splenic PHSC activity in donors given SI factor for 7 days followed by 5FU, compared with the 500% increase in those just given S1 factor (Fig 1) . The single 5FU treatment in experiment 2 caused about a twofold reduction in repopulating ability in controls, possibly because the 5 F U was old; no reduction was found using the same batch of 5FU 2 and 3 years ear lie^.'^.'' A slight excess of PHSC migration from the marrow, relative to PHSC proliferation in the marrow, would explain the loss in marrow activity in Table 1 . However migration alone seems inadequate to account for the large increase of PHSC in the spleen. It probably contributes, as experiment 3 (last paragraph in Results) found a large increase in blood nucleated cells and substantial long-term repopulating activity in the blood after 7 days of S1 treatment.
Perhaps activity of splenic PHSC can increase greatly because, unlike the marrow, the spleen can increase greatly in volume. Marrow space in mice is limited by their small bones. It is also possible that the spleen is where S1 factor concentrates from the subcutaneous injection site. These pos-sibilities may explain why PHSC proliferate in the spleen, but not in the marrow in response to S1 factor. They may also explain numerous reports in which various growth factors in vivo enhance hematopoiesis in the spleen with little or no effect on cells in the marrow. S1 factor is known to stimulate a variety of hematopoietic cells to d i~i d e , * *~~~~" ' especially in combination with other growth factors." Others also recently reported that S1 factor greatly increases PHSC activity in spleen and blood12.'3; we confirm and extend those reports by showing that cell proliferation is required for those effects. The deleterious effects of 5FU on day 4 suggest that S1 factor stimulates PHSC to proliferate thus making them vulnerable to cytotoxic agents as suggested by Moore.14 The response of normal PHSC to S1 factor may explain why the myeloid and lymphoid systems of W-anemic mutants with defective c-kit receptors6-* are repopulated by mar- Experiment 3 shown here. Same as experiment 1, except that each B6 recipient was given 1.6 x I O 6 fresh marrow from the competitor pool, mixed with amounts and types of B6-Hbbd GP/-I" donor cells given below. No factor controls received seven daily injections with HBSS, whereas both SI factor and SI factor with 5FU groups were given seven daily injections of SI factor as in Table 1 ; the SI factor with 5FU group also received 5FU on day 4 of SI factor injections; donor cells were removed and injected 1 day after the seventh injection of SI factor. In the spleen, blood, and liver suspensions, the fraction mixed with competitor marrow and injected into recipients had the same density as lymphocytes after separation on LSM. L and E were tested after 11 1 days, with an average of 3.6 recipients per value. By 2 factor ANOVA, no significant changes resulted in marrows; in spleens, %E or %L were higher in the "SI factor" group than in the other groups ( P = .OOOlI. * RU for the donor cell numbers injected from blood, liver, marrow, and spleen, respectively, which are (x106) for No factor: 0.25,0.4, 1.6, and 1.6; for SI factor: 1.3, 0.4, 1.6, and 1.6; for SI factor with 5FU: 0.1, 0.4, 1.6, and 1.6. To calculate total RU per donor ( R U d , the RU for cell numbers injected are divided by the fractions of total cells that were injected per donor. In blood, liver, marrow, and spleen, percentages injected were for No factor: 50, 15, 4, and 12; for SI factor: 75, 38, 3, and 10; and for SI factor with 5FU: 75, 30, 8, and 15.
row transplantation without irradiati~n."~ Normal PHSC would respond better to the in situ S1 factor and outcompete the defective PHSC of the W-anemics. This supports our conclusion that increased levels of S1 factor alone can stimulate PHSC proliferation in vivo.
